Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GE Healthcare and Rapidscan Pharma Solutions have launched Rapiscan (regadenoson), a selective A2A adenosine receptor agonist approved as a pharmacological stress agent for myocardial perfusion scintigraphy in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease, in the UK.
Subscribe to our email newsletter
Rapidscan Pharma claims Rapiscan is a non-weight based, infusion pump-free pharmacological stress agent available in the UK.
Unlike older agents, Rapiscan requires no dose adjustment for varying body weight and is administered as a 10 second injection, which cuts the need for an infusion pump, extension line and infusion line set-up.
Regadenoson was discovered and developed by CV Therapeutics and was approved by the US Food and Drug Administration in April 2008, where it is sold by Astellas Pharma US.
Gilead Sciences acquired CV Therapeutics in 2009.
EU Commission Licence was granted by the European Medicine Agency in September 2010.
In the UK and Germany, Rapiscan (regadensoson) is distributed by GE Healthcare.